Santomaggio C, Tucci E, Rinaldini M, Algeri R, Righi R, Pepi F, Ghezzi P, Andrei A, Bellezza A
Department of Pneumology, Azienda Ospedaliera Careggi, Florence, Italy.
Am J Clin Oncol. 1998 Feb;21(1):67-71. doi: 10.1097/00000421-199802000-00015.
The aim of this study was to identify a chemotherapy combination that would be active and well tolerated for palliative treatment of advanced non-small-cell lung cancer (NSCLC). From February 1992 to December 1994, a total of 77 patients affected by stage-IIIB and stage-IV NSCLC were treated with carboplatin 350 mg/m2 on day 1 and vinorelbine 25 mg/m2 on days 1 and 8 of each cycle, with cycles repeated every 28 days. All patients were evaluable for response and toxicity. A total of 24 patients showed a partial response (31% response rate; 95% CI = 21-41%). The median duration of overall survival was 41 weeks (95% CI = 31-51), and the median time to disease progression was 34 weeks (95% CI = 25-43). The treatment was well tolerated: no grade-4 toxicity was observed. The carboplatin-vinorelbine combination deserves to considered as a valid alternative to regimens that include cisplatin for palliative treatment of advanced NSCLC.
本研究的目的是确定一种对晚期非小细胞肺癌（NSCLC）姑息治疗有效且耐受性良好的化疗方案组合。1992年2月至1994年12月，共有77例IIIB期和IV期NSCLC患者接受治疗，每个周期第1天给予卡铂350mg/m²，第1天和第8天给予长春瑞滨25mg/m²，每28天重复一个周期。所有患者均评估疗效和毒性。共有24例患者出现部分缓解（缓解率31%；95%CI=21-41%）。总生存期中位数为41周（95%CI=31-51），疾病进展时间中位数为34周（95%CI=25-43）。该治疗耐受性良好：未观察到4级毒性。卡铂-长春瑞滨联合方案值得被视为晚期NSCLC姑息治疗中含顺铂方案的有效替代方案。
